Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
The company's investment will expand its US manufacturing footprint and is the largest investment of its kind in history.
Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.
Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...